TY - JOUR
T1 - Cefepime-induced encephalopathy in a COVID-19 patient
T2 - a case report
AU - Nakamura, Tomoyuki
AU - Yatabe, Tomoaki
AU - Kuriyama, Naohide
AU - Hiraiwa, Toshihisa
AU - Matsumoto, Kana
AU - Nishida, Osamu
N1 - Publisher Copyright:
© 2022, The Author(s) under exclusive licence to Japanese Society of Anesthesiologists.
PY - 2022/6
Y1 - 2022/6
N2 - Prolonged neurological symptoms such as “brain fog” and cognitive impairment have occurred after coronavirus disease 2019 (COVID-19) infection. In this report, we describe impaired consciousness caused by cefepime hydrochloride (CFPM) in a patient with cognitive sequalae of COVID-19. A 56-year-old male patient was diagnosed with penile abscess after COVID-19 infection, and a blood culture detected two drug-resistant Pseudomonas aeruginosa strains. Therefore, CFPM 2 g × twice/day was administered on day 71 after intensive care unit admission. Approximately 48 h after CFPM administration, the patient showed disturbances in consciousness. Contrast-enhanced computed tomography, magnetic resonance imaging, and spinal fluid examination revealed no obvious abnormalities. Therefore, CFPM-induced neurotoxicity was suspected. CFPM was discontinued and ceftazidime 2 g × three times/day was initiated. The patient's consciousness improved 30 h after the final administration of CFPM. Serum CFPM concentrations were 14.2, 21.7, 21.7, and 11.9 μg/mL on days 1, 2, and 3 after the initiation of CFPM and on the day after CFPM was discontinued, respectively. In conclusion, intensivists should pay attention to new neurological symptoms such as CFPM-induced encephalopathy in patients with prolonged neurological symptoms after COVID-19 infection.
AB - Prolonged neurological symptoms such as “brain fog” and cognitive impairment have occurred after coronavirus disease 2019 (COVID-19) infection. In this report, we describe impaired consciousness caused by cefepime hydrochloride (CFPM) in a patient with cognitive sequalae of COVID-19. A 56-year-old male patient was diagnosed with penile abscess after COVID-19 infection, and a blood culture detected two drug-resistant Pseudomonas aeruginosa strains. Therefore, CFPM 2 g × twice/day was administered on day 71 after intensive care unit admission. Approximately 48 h after CFPM administration, the patient showed disturbances in consciousness. Contrast-enhanced computed tomography, magnetic resonance imaging, and spinal fluid examination revealed no obvious abnormalities. Therefore, CFPM-induced neurotoxicity was suspected. CFPM was discontinued and ceftazidime 2 g × three times/day was initiated. The patient's consciousness improved 30 h after the final administration of CFPM. Serum CFPM concentrations were 14.2, 21.7, 21.7, and 11.9 μg/mL on days 1, 2, and 3 after the initiation of CFPM and on the day after CFPM was discontinued, respectively. In conclusion, intensivists should pay attention to new neurological symptoms such as CFPM-induced encephalopathy in patients with prolonged neurological symptoms after COVID-19 infection.
UR - http://www.scopus.com/inward/record.url?scp=85129412749&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129412749&partnerID=8YFLogxK
U2 - 10.1007/s00540-022-03068-1
DO - 10.1007/s00540-022-03068-1
M3 - Article
C2 - 35487992
AN - SCOPUS:85129412749
SN - 0913-8668
VL - 36
SP - 432
EP - 435
JO - Journal of Anesthesia
JF - Journal of Anesthesia
IS - 3
ER -